A team of researchers in Japan has succeeded in differentiating cardiac precursor-like cells from mesenchymal stem cells that were derived from human menstrual blood.
Aldagen Inc. has announced the beginning of Phase III clinical trials in which the first pediatric patient has been treated with a proprietary adult stem cell product specifically developed as a therapeutic modality for inherited metabolic diseases.
Researchers in Italy have successfully mobilized stem cells that naturally reside in the body to treat critical limb ischemia in an animal model.
The biotech company Pluristem Therapeutics Inc. has found improvement in an animal model of multiple sclerosis with the use of a therapeutic product developed from mesenchymal stromal cells.
As the first clinical trials ever to be conducted in the U.S. with embryonic stem cells are about to commence, FDA regulators convene a special meeting to debate the inherent risks and dangers.
The biotech company Pluristem Therapeutics Inc. has found improvement in an animal model of ischemic stroke with the use of a therapeutic product developed from mesenchymal stromal cells.
Toll Free:
1-800-980-STEM (7836)
Outside or Inside US Call:
1-954-358-3382
Toll Free Fax (US Only):
1-866-755-3951
From Outside US Fax:
1-775-887-1194
Copyright 2024, Stem Cell Insitute Panama. All rights reserved.
